The Gilles de la Tourette Syndrome–Quality of Life Scale (GTS-QOL)
Development and validation
Abstract
Background: Gilles de la Tourette syndrome (GTS) is a chronic neuropsychiatric disorder which has a significant detrimental impact on the health-related quality of life (HR-QOL) of patients. However, no patient-reported HR-QOL measures have been developed for this population.
Objective: The development and validation of a new scale for the quantitative assessment of HR-QOL in patients with GTS.
Methods: In stage 1 (item generation), a pool of 40 potential scale items was generated based on interviews with 133 GTS outpatients, literature review, and consultation with experts. In stage 2 (scale development), these items were administered to a sample of 192 GTS outpatients. Standard statistical methods were used to develop a rating scale satisfying criteria for acceptability, reliability, and validity. In stage 3 (scale evaluation), the psychometric properties of the resulting scale were tested in a second sample of 136 subjects recruited through the UK-Tourette Syndrome Association.
Results: Response data analysis and item reduction methods led to a final 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive). The GTS-QOL demonstrated satisfactory scaling assumptions and acceptability; both internal consistency reliability and test-retest reliability were high (Cronbach alpha ≥0.8 and intraclass correlation coefficient ≥0.8); validity was supported by interscale correlations (range 0.5–0.7), confirmatory factor analysis, and correlation patterns with other rating scales and clinical variables.
Conclusions: The Gilles de la Tourette syndrome (GTS)–specific health-related quality of life (HR-QOL) scale (GTS-QOL) is proposed as a new disease-specific patient-reported scale for the measurement of HR-QOL in patients with GTS, taking into account the complexity of the clinical picture of GTS.
Get full access to this article
View all available purchase options and get full access to this article.
Supplementary Material
REFERENCES
1.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed, text revision) (DSM-IV-TR). Washington, DC: APA; 2000.
2.
Robertson MM. The international prevalence, epidemiology, and clinical phenomenology of Gilles de la Tourette syndrome. J Psychosom Res 2008 (in press).
3.
Robertson MM. Tourette syndrome, associated conditions and the complexities of treatment. Brain 2000;123:425–462.
4.
Cavanna AE, Servo S, Monaco F, Robertson MM. More than tics: the behavioral spectrum of Gilles de la Tourette syndrome. J Neuropsychol Clin Neurosci 2008 (in press).
5.
Devinsky O. Outcome research in neurology: incorporating health-related quality of life. Ann Neurol 1995;37:141–142.
6.
Müller J, Wissel J, Kemmler G, et al. Craniocervical dystonia questionnaire (CDQ-24): development and validation of a disease-specific quality of life instrument. J Neurol Neurosurg Psychiatry 2004;75:749–753.
7.
Tan EK, Fook-Chong S, Lum S-Y, Thumboo J. Validation of a short disease specific quality of life scale for hemifacial spasm: correlation with SF-36. J Neurol Neurosurg Psychiatry 2005;76:1707–1710.
8.
Schrag A, Selai C, Quinn N, et al. Measuring quality of life in PSP: The PSP-QOL. Neurology 2006;67:39–44.
9.
Elstner K, Selai CE, Trimble MR, et al. Quality of life (QOL) of patients with Gilles de la Tourette’s syndrome. Acta Psychiatrica Scand 2001;103:52–59.
10.
Selai CE, Trimble MR. The Revised Quality of Life Assessment Schedule (QOLAS): User Manual. London: Institute of Neurology, University College; 1998.
11.
Brazier JE, Harper R, Jones NM, et al. Validating the SF 36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160–164.
12.
Nagata C, Ido M, Shimizu H, et al. The choice of response scale for health measurement: comparison of 4, 5, and 7-point scales and visual analog scale. J Epidemiol 1996;6:192–197.
13.
Robertson MM, Eapen V. The National Hospital Interview Schedule for the assessment of Gilles de la Tourette syndrome and related behaviours. Int J Methods Psychiatr Res 1996;6:203–226.
14.
Leckman JF, Riddle MA, Hardin MT, et al. The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566–573.
15.
De Geus F, Denys D. Pitfalls in factor analytic techniques. Am J Psychiatry 2004;161:579–580.
16.
Reise SP, Waller NG, Comrey AL. Factor analysis and scale revision. Psychol Assess 2000;12:287–297.
17.
Ferguson E, Cox T. Exploratory factor analysis: a user’s guide. Int J Select Assess 1993;1:84–94.
18.
Guyatt GH, Jaeschke R, Feeny DH, Patrick DL. Measurements in clinical trials: choosing the right approach. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1996:41–48.
19.
Ware JE, Harris WJ, Gandek B, Rogers BW, Reese PR. MAP-R for windows: multitrait/multi-item analysis program-revised user’s guide. Boston: Health Assessment Laboratory; 1997.
20.
Velicer WF, Fava JL. Effects of variable and subject sampling on factor pattern recovery. Psychol Meth 1998;3:231–251.
21.
Gaffney GR, Sieg K, Hellings J. The MOVES: a self-rating scale for Tourette’s syndrome. J Child Adolesc Psychopharmacol 1994;4:269–280.
22.
Schrag A, Selai C, Jahanshahi M, et al. The EQ-5D—a generic quality of life measure—is a useful instrument to measure quality of life in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 2000;69:67–73.
23.
Juniper EF, Guyatt GH, Jaeschke R. How to develop and validate a new health-related quality of life instrument. In: Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven; 1996.
24.
Marx RG, Bombardier C, Hogg-Johnson S, Wright JG. Clinimetric and psychometric strategies for development of a health measurement scale. J Clin Epidemiol 1999;52:105–111.
25.
Hobart J, Lamping D, Fitzpatrick R, Riazi A, Thompson A. The Multiple Sclerosis Impact Scale (MSIS-29): a new patient-based outcome measure. Brain 2001;124:962–973.
26.
Brazier JE, Harper R, Jones NM, et al. Validating the SF-36 health survey questionnaire: new outcome measure for primary care. BMJ 1992;305:160–164.
27.
Freeman JA, Hobart JC, Langdon DW, Thompson AJ. Clinical appropriateness: a key factor in outcome measure selection: the 36 item short form health survey in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:150–156.
28.
Janse AJ, Gemke RJBJ, Uiterwaal CSPM, van der Tweel I, Kimpen JLL, Sinnema G. Quality of life: patients and doctors don’t always agree: a meta-analysis. J Clin Epidemiol 2004;57:653–661.
29.
Bernard BA, Stebbins GT, Siegel S, et al. The impact of co-morbidities on quality of life in Gilles de la Tourette syndrome. Neurology 2006;66 (suppl 2):A365–366.
30.
Storch EA, Merlo LJ, Lack C, et al. Quality of life in youth with Tourette’s syndrome and chronic tic disorder. J Clin Child Adolesc Psychol 2007;36:217–227.
31.
Storch EA, Lack C, Simons LE, Goodman WK, Murphy TK, Geffken GR. A measure of functional impairment in youth with Tourette’s syndrome. J Pediatr Psychol 2007;32:950–959.
Information & Authors
Information
Published In
Copyright
© 2008.
Publication History
Published online: October 27, 2008
Published in print: October 28, 2008
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Family functioning mediation in tic severity and quality of life for children with Tourette syndrome, World Journal of Psychiatry, 14, 11, (1641-1651), (2024).https://doi.org/10.5498/wjp.v14.i11.1641
- Aberrant Functional Connectivity of the Salience Network in Adult Patients with Tic Disorders: A Resting-State fMRI Study, eneuro, 11, 6, (ENEURO.0223-23.2024), (2024).https://doi.org/10.1523/ENEURO.0223-23.2024
- Tourette Syndrome, Neurology, 103, 2, (2024)./doi/10.1212/WNL.0000000000209572
- Slips of the tongue in patients with Gilles de la Tourette syndrome, Neurological Research and Practice, 6, 1, (2024).https://doi.org/10.1186/s42466-024-00324-5
- The psychometric properties of Chinese version of the Gilles de la Tourette syndrome-quality of life scale (GTS-QOL) for children and adolescents, BMC Psychiatry, 24, 1, (2024).https://doi.org/10.1186/s12888-024-06149-5
- Pain in Tourette Syndrome: A Comprehensive Review, Journal of Child and Adolescent Psychopharmacology, (2024).https://doi.org/10.1089/cap.2024.0025
- Use of Medical Cannabis in Patients with Gilles de la Tourette's Syndrome in a Real-World Setting, Cannabis and Cannabinoid Research, 9, 1, (293-299), (2024).https://doi.org/10.1089/can.2022.0112
- Coping with Tourette’s syndrome: a meta-ethnography of individual and family perspectives, Psychology & Health, (1-23), (2024).https://doi.org/10.1080/08870446.2024.2360126
- Validation and assessment of the self-injurious behavior scale for tic disorders (SIBS-T), Scientific Reports, 14, 1, (2024).https://doi.org/10.1038/s41598-024-66528-6
- From compulsivity to compulsion: the neural basis of compulsive disorders, Nature Reviews Neuroscience, 25, 5, (313-333), (2024).https://doi.org/10.1038/s41583-024-00807-z
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.